专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014152092A2 METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION 审中-公开
标题翻译：调节调节性T细胞功能的方法和组合物
公开(公告)号：WO2014152092A2
公开(公告)日：2014-09-25
申请号：PCT/US2014/026940
申请日：2014-03-14
申请人： WANG, Rongfu
发明人： WANG, Rongfu
IPC分类号： A61K39/00
CPC分类号： A61K31/5383 , A01K67/0278 , A01K2207/15 , A01K2217/052 , A01K2227/105 , A01K2267/0387 , A61K31/47 , A61K31/4704 , A61K31/4709 , A61K31/4741 , A61K31/496 , A61K31/519 , A61K31/55 , A61K39/0011 , A61K39/39 , A61K45/06 , C07K14/705 , G01N33/505 , Y02A50/412
摘要： Pharmaceutical compositions comprising a compound selected from the group consisting of Compound Nos. 1, 2, 3, 4, 5, 6, 7, 13, 22, 23, 24 and 25, which are described in Table 1, and a pharmaceutically acceptable excipient. The pharmaceutical composition of the invention may further comprise an antigen, and/or an adjuvant. Also provided are methods of inhibiting a regulatory T (Treg) cell-mediated immune suppression, or more generally a method for enhancing immune response using a pharmaceutical composition comprising a ligand for human Toll-like receptor (TLR) 8 which activates the MyD88-IRAK4 signalling pathway. The present invention further provides a method of screening for an inhibitor of Treg cells' suppressive activity of host immune response using CD4+ Treg cells which express CD25, GITR and FoxP3; secrete IL-10, and are able to suppress the activation of CD4+ T cells.
摘要翻译：包含选自表1中描述的化合物编号1,2,3,4,5,6,7,13,22,23,24和25的化合物的药物组合物和药学上可接受的赋形剂。本发明的药物组合物还可以包含抗原和/或佐剂。还提供了抑制调节T（Treg）细胞介导的免疫抑制的方法，或更一般地，使用包含人类Toll样受体（TLR）8的配体的药物组合来增强免疫应答的方法，其激活MyD88-IRAK4 信号通路。本发明还提供了使用表达CD25，GITR和FoxP3的CD4 + Treg细胞筛选Treg细胞抑制宿主免疫应答的抑制剂的方法; 分泌IL-10，能够抑制CD4 + T细胞的活化。

2. 发明申请

WO2022046800A2 BECLIN 2 AND USES THEREOF FOR TREATING CANCER AND NEURODEGENERATIVE DISEASES 审中-公开
公开(公告)号：WO2022046800A2
公开(公告)日：2022-03-03
申请号：PCT/US2021/047388
申请日：2021-08-24
申请人： UNIVERSITY OF SOUTHERN CALIFORNIA , THE METHODIST HOSPITAL SYSTEM , WANG, Rongfu , WANG, Yicheng , ZHU, Motao
发明人： WANG, Rongfu , WANG, Yicheng , ZHU, Motao
IPC分类号： C07K19/00 , A61K47/42 , C07K14/00 , C07K14/435 , C07K14/705
摘要： Disclosed herein are recombinant proteins and/or polypeptides comprising a Beclin 2 polypeptide and/or a targeting moiety and methods relating to treating, preventing, reducing, and/or inhibiting a cancer, metastasis, and/or a neurodegenerative disease comprising administering said recombinant protein or polypeptides.

3. 发明申请

WO2014047085A3 PROSTATE-SPECIFIC TUMOR ANTIGEN AND USES THEREOF 审中-公开
标题翻译：前列腺特异性肿瘤抗原及其用途
公开(公告)号：WO2014047085A3
公开(公告)日：2015-07-23
申请号：PCT/US2013060254
申请日：2013-09-18
申请人： WANG RONGFU
发明人： WANG RONGFU
IPC分类号： A61K39/00 , A61P35/00
CPC分类号： A61K38/1703 , A61K38/193 , A61K39/0011 , A61K2300/00
摘要： Twenty-one PSGR-derived peptides predicted by an immuno-informatics approach based on the HLA-A2 binding motif were examined for their ability to induce peptide-specific T cell responses in peripheral blood mononuclear cells (PBMCs) obtained from either HLA-A2+ healthy donors or HLA-A2+ prostate cancer patients. The recognition of HLA-A2 positive and PSGR expressing LNCaP cells was also tested. Three peptides, PSGR3, PSGR4 and PSGR14 frequently induced peptide-specific T cell responses in PBMCs from both healthy donors and prostate cancer patients, and are recognized by CD8+ T cells in an HLA-A2 dependent manner. These peptide-specific T cells recognize HLA-A2+ and PSGR+ tumor cells, and killed LNCaP prostate cancer cells in an HLA class I-restricted manner. These PSGR-derived peptides identified are useful as diagnostic markers as well as immune targets for anticancer vaccines.
摘要翻译：检测了通过基于HLA-A2结合基序的免疫信息学方法预测的21种PSGR衍生肽在从HLA-A2 +健康获得的外周血单核细胞（PBMC）中诱导肽特异性T细胞应答的能力供体或HLA-A2 +前列腺癌患者。还测试了表达HLA-A2阳性和PSGR的LNCaP细胞的识别。三种肽，PSGR3，PSGR4和PSGR14经常诱导来自健康供体和前列腺癌患者的PBMC中的肽特异性T细胞应答，并且被CD8 + T细胞以HLA-A2依赖性方式识别。这些肽特异性T细胞识别HLA-A2 +和PSGR +肿瘤细胞，并以HLA I类限制的方式杀死LNCaP前列腺癌细胞。鉴定的这些PSGR衍生肽可用作抗癌疫苗的诊断标记物和免疫靶标。

4. 发明申请

WO2014134084A3 PHF20 AND JMJD3 COMPOSITIONS AND METHODS OF USE IN CANCER IMMUNOTHERAPY 审中-公开
标题翻译： PHF20和JMJD3组合物及其在癌症免疫治疗中的应用
公开(公告)号：WO2014134084A3
公开(公告)日：2014-12-24
申请号：PCT/US2014018464
申请日：2014-02-26
申请人： WANG RONGFU , WANG YICHEN , ZHAO WEI
发明人： WANG RONGFU , WANG YICHEN , ZHAO WEI
IPC分类号： A61K38/00 , A61K38/03
CPC分类号： C07K14/4702 , A61K35/15 , A61K38/08 , A61K39/0011 , A61K39/3955 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/76 , C12N5/0696 , C12N15/1138 , C12N2310/14 , C12N2320/30 , G01N33/56977 , G01N2333/52 , G01N2500/10
摘要： Pharmaceutical compositons and methods for regulating somatic cell reprogramming in mammals, and in particular, for positively and negatively regulating cell reprogramming in human cells in vivo and in vitro. The invention also provides PHF20-derived compositions and methods useful for cancer immunotherapies, including breast cancer therapies in particular.
摘要翻译：用于调节哺乳动物体细胞重编程的药物组合物和方法，特别是用于在体内和体外对人细胞中的细胞重编程进行正负调节。本发明还提供了用于癌症免疫疗法的PHF20衍生组合物和方法，特别是包括乳腺癌治疗。

5. 发明申请

WO2014152092A3 METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION 审中-公开
标题翻译：调节调节性T细胞功能的方法和组合物
公开(公告)号：WO2014152092A3
公开(公告)日：2014-11-20
申请号：PCT/US2014026940
申请日：2014-03-14
申请人： WANG RONGFU
发明人： WANG RONGFU
IPC分类号： A61K39/00
CPC分类号： A61K31/5383 , A01K67/0278 , A01K2207/15 , A01K2217/052 , A01K2227/105 , A01K2267/0387 , A61K31/47 , A61K31/4704 , A61K31/4709 , A61K31/4741 , A61K31/496 , A61K31/519 , A61K31/55 , A61K39/0011 , A61K39/39 , A61K45/06 , C07K14/705 , G01N33/505
摘要： Pharmaceutical compositions comprising a compound selected from the group consisting of Compound Nos. 1, 2, 3, 4, 5, 6, 7, 13, 22, 23, 24 and 25, which are described in Table 1, and a pharmaceutically acceptable excipient. The pharmaceutical composition of the invention may further comprise an antigen, and/or an adjuvant. Also provided are methods of inhibiting a regulatory T (Treg) cell-mediated immune suppression, or more generally a method for enhancing immune response using a pharmaceutical composition comprising a ligand for human Toll-like receptor (TLR) 8 which activates the MyD88-IRAK4 signalling pathway. The present invention further provides a method of screening for an inhibitor of Treg cells' suppressive activity of host immune response using CD4+ Treg cells which express CD25, GITR and FoxP3; secrete IL-10, and are able to suppress the activation of CD4+ T cells.
摘要翻译：包含选自表1中描述的化合物1,2,3,4,5,6,7,13,22,23,24和25的化合物和药学上可接受的赋形剂的药物组合物。本发明的药物组合物可以进一步包含抗原和/或佐剂。还提供了抑制调节性T（Treg）细胞介导的免疫抑制的方法，或者更一般地使用包含用于激活MyD88-IRAK4的人类Toll样受体（TLR）8的配体的药物组合物增强免疫应答的方法信号通路。本发明进一步提供了使用表达CD25，GITR和FoxP3的CD4 + Treg细胞筛选Treg细胞抑制宿主免疫应答活性的抑制剂的方法; 分泌IL-10，并且能够抑制CD4 + T细胞的活化。

6. 发明申请

WO2014134084A2 PHF20 AND JMJD3 COMPOSITIONS AND METHODS OF USE IN CANCER IMMUNOTHERAPY 审中-公开
标题翻译： PHF20和JMJD3组合物以及用于癌症免疫治疗的方法
公开(公告)号：WO2014134084A2
公开(公告)日：2014-09-04
申请号：PCT/US2014/018464
申请日：2014-02-26
申请人： WANG, Rongfu , WANG, Yichen , ZHAO, Wei
发明人： WANG, Rongfu , WANG, Yichen , ZHAO, Wei
IPC分类号： A61K48/00 , A61K38/17
CPC分类号： C07K14/4702 , A61K35/15 , A61K38/08 , A61K39/0011 , A61K39/3955 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/76 , C12N5/0696 , C12N15/1138 , C12N2310/14 , C12N2320/30 , G01N33/56977 , G01N2333/52 , G01N2500/10
摘要： Pharmaceutical compositons and methods for regulating somatic cell reprogramming in mammals, and in particular, for positively and negatively regulating cell reprogramming in human cells in vivo and in vitro. The invention also provides PHF20-derived compositions and methods useful for cancer immunotherapies, including breast cancer therapies in particular.
摘要翻译：用于调节哺乳动物体细胞重编程的药物组合物和方法，特别是用于在体内和体外正负调节人细胞中的细胞重编程的药物组合物和方法。本发明还提供了PHF20衍生的组合物和可用于癌症免疫疗法的方法，特别包括乳腺癌疗法。

7. 发明申请

WO2014047085A2 PROSTATE-SPECIFIC TUMOR ANTIGEN AND USES THEREOF 审中-公开
标题翻译：前列腺特异性肿瘤抗原及其用途
公开(公告)号：WO2014047085A2
公开(公告)日：2014-03-27
申请号：PCT/US2013/060254
申请日：2013-09-18
申请人： WANG, Rongfu
发明人： WANG, Rongfu
IPC分类号： A61K38/19
CPC分类号： A61K38/1703 , A61K38/193 , A61K39/0011 , A61K2300/00
摘要： Twenty-one PSGR-derived peptides predicted by an immuno-informatics approach based on the HLA-A2 binding motif were examined for their ability to induce peptide-specific T cell responses in peripheral blood mononuclear cells (PBMCs) obtained from either HLA-A2+ healthy donors or HLA-A2+ prostate cancer patients. The recognition of HLA-A2 positive and PSGR expressing LNCaP cells was also tested. Three peptides, PSGR3, PSGR4 and PSGR14 frequently induced peptide-specific T cell responses in PBMCs from both healthy donors and prostate cancer patients, and are recognized by CD8+ T cells in an HLA-A2 dependent manner. These peptide-specific T cells recognize HLA-A2+ and PSGR+ tumor cells, and killed LNCaP prostate cancer cells in an HLA class I-restricted manner. These PSGR-derived peptides identified are useful as diagnostic markers as well as immune targets for anticancer vaccines.
摘要翻译：检测了通过基于HLA-A2结合基序的免疫信息学方法预测的21种PSGR衍生肽在从HLA-A2 +健康获得的外周血单核细胞（PBMC）中诱导肽特异性T细胞应答的能力供体或HLA-A2 +前列腺癌患者。还测试了表达HLA-A2阳性和PSGR的LNCaP细胞的识别。三种肽，PSGR3，PSGR4和PSGR14经常诱导来自健康供体和前列腺癌患者的PBMC中的肽特异性T细胞应答，并且被CD8 + T细胞以HLA-A2依赖性方式识别。这些肽特异性T细胞识别HLA-A2 +和PSGR +肿瘤细胞，并以HLA I类限制的方式杀死LNCaP前列腺癌细胞。鉴定的这些PSGR衍生肽可用作抗癌疫苗的诊断标记物和免疫靶标。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式